Compare QSR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSR | TEVA |
|---|---|---|
| Founded | 1954 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 30.2B |
| IPO Year | 2006 | N/A |
| Metric | QSR | TEVA |
|---|---|---|
| Price | $67.92 | $30.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $73.94 | $32.11 |
| AVG Volume (30 Days) | 2.7M | ★ 8.8M |
| Earning Date | 02-11-2026 | 01-28-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.81 | 0.62 |
| Revenue | $9,264,000,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $12.57 | $4.62 |
| Revenue Next Year | $3.92 | $0.34 |
| P/E Ratio | ★ $24.32 | $50.57 |
| Revenue Growth | ★ 16.82 | 0.02 |
| 52 Week Low | $58.71 | $12.47 |
| 52 Week High | $73.70 | $31.99 |
| Indicator | QSR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 70.32 |
| Support Level | $68.80 | $31.17 |
| Resistance Level | $70.05 | $31.99 |
| Average True Range (ATR) | 0.91 | 0.55 |
| MACD | -0.37 | -0.19 |
| Stochastic Oscillator | 21.03 | 57.08 |
Restaurant Brands generates about $44 billion in system sales across more than 32,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,082 stores), Tim Hortons (4,539), Popeyes (3,520), and Firehouse Subs (1,345), concentrated in the US and Canada, with these brands also comprising 15,639 franchised international locations as of year-end 2024. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.